MGF (Mechano-Growth Factor)

Volume Pricing

Price per pack (10 vials). Discount applies to this compound only – no mix and match.

MGF — Mechano Growth Factor / IGF-1 Splice Variant for Tissue Repair Research

Mechano Growth Factor (MGF) is an alternatively spliced isoform of insulin-like growth factor 1 (IGF-1), generated from the IGF-1 gene in response to mechanical load, tissue damage, or hypoxia. The splice variant inserts a distinct 49-base-pair exon into the IGF-1 mRNA, producing a peptide with a unique C-terminal E-domain not present in systemic IGF-1Ea or IGF-1Eb isoforms. Geoffrey Goldspink and colleagues at University College London characterized MGF’s distinct biological activity during the 1990s, demonstrating that its E-domain activates skeletal muscle satellite cells through a receptor pathway independent of the systemic IGF-1 receptor. This independence from IGF-1R is the defining feature separating MGF’s signaling from circulating IGF-1 and distinguishes it mechanistically from recombinant IGF-1 used in standard growth factor research.

Why MGF’s E-Domain Signaling Matters

The C-terminal E-domain peptide (sometimes studied independently as the MGF E-peptide) appears to engage a binding site distinct from IGF-1R, triggering satellite cell proliferation — the first step in skeletal muscle repair — without requiring the systemic IGF-1 axis. Systemic IGF-1 drives differentiation of myoblasts into mature muscle fibers; MGF appears to act upstream, expanding the progenitor pool before differentiation. Researchers studying the temporal sequence of muscle repair or satellite cell activation in isolation use MGF to interrogate this upstream step separately from downstream differentiation signals. MGF’s very short native half-life (minutes in plasma) has prompted parallel research into PEGylated MGF analogues that extend action while preserving E-domain activity.

Research Applications

MGF is used in studies examining:

• Skeletal muscle satellite cell activation and progenitor pool dynamics
• Tissue repair sequencing — separating upstream progenitor expansion from downstream differentiation
• Mechanotransduction biology and load-sensitive gene expression
• Cardiac repair models following ischemic injury
• Neuroprotection in hypoxia and degenerative disease models
• PEGylated peptide half-life extension research
• Comparative IGF-1 isoform pharmacology (MGF vs IGF-1Ea vs IGF-1Eb)

Specifications

Reconstitution

MGF arrives as lyophilized powder and must be reconstituted with bacteriostatic water prior to use. Use the formula:

Total mg ÷ Volume added (mL) = Concentration (mg/mL)

Example: 2mg vial + 1mL BAC water = 2mg/mL solution

Reconstituted peptide should be stored at 2–8°C and used within 28–30 days. Given MGF’s short in vivo half-life, reconstituted solutions should be used promptly after preparation.

Protocol Notes

Animal model literature provides the primary quantitative framework for MGF research dosing. Human data is limited; most published work is in rodent and in vitro muscle cell systems. The short half-life has led many research groups to use local injection directly at the target tissue site rather than systemic administration.

• Dose range: 100–200mcg per administration observed in rodent muscle repair models
• Frequency: Single post-injury administration or every-other-day dosing studied; timing relative to mechanical stimulus is a key variable in published protocols
• Study duration: 1–3 weeks in most repair and satellite cell studies

Research Stacks

MGF is commonly paired in research settings with:

• IGF-1 LR3 — MGF is an IGF-1 splice variant that signals through a distinct C-terminal domain to activate satellite cells acutely; IGF-1 LR3 then sustains IGF-1R engagement over a longer half-life period. Researchers pair them to study early-phase satellite cell recruitment alongside sustained downstream anabolic signaling.
• GHRP-2 — GHRP-2 drives pulsatile GH secretion via the ghrelin receptor, transiently elevating endogenous IGF-1; co-administration with MGF is studied to examine whether upstream GH-axis stimulation potentiates or confounds the local IGF-1 splice variant activity measured in mechanical loading models.
• BPC-157 — BPC-157 supports tendon and connective tissue repair through NO and growth factor pathways; combining it with MGF is studied in musculoskeletal injury models where both myogenic and connective tissue repair endpoints are of interest.

Purity Guarantee

Every batch is ≥99% purity. If you independently test your compound and the results don’t match — send us the COA and we’ll issue store credit, no questions asked.